Several IL-1β blocking monoclonal antibodies are currently being developed for autoimmune disorders including rheumatoid arthritis, cryopyrin-associated periodic syndrome, diabetes, and gout [47–49]. This evidence concerns the gene IL1B and cryopyrin-associated periodic syndrome.